Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

CH Hsu, YC Shen, ZZ Lin, PJ Chen, YY Shao… - Journal of …, 2010 - Elsevier
BACKGROUND & AIMS: Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was
recently approved for the treatment of advanced hepatocellular carcinoma (HCC) …
被引用次数：145 相关文章

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

CH Hsu, YC Shen, ZZ Lin, PJ Chen… - Journal of …, 2010 - pubmed.ncbi.nlm.nih.gov
Background & aims Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was
recently approved for the treatment of advanced hepatocellular carcinoma (HCC) …

[引用][C] Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

HSU CH - J Hepatol, 2010 - cir.nii.ac.jp
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced
hepatocellular carcinoma | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

CH Hsu, YC Shen, ZZ Lin, PJ Chen, YY Shao… - Journal of …, 2010 - infona.pl
Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for
the treatment of advanced hepatocellular carcinoma (HCC). Metronomic chemotherapy …

Phase Ii Study of Combining Sorafenib with Metronomic Tegafur/Uracil for Advanced Hepatocellular Carcinoma

CH HSU, YC SHEN, ZZHE LIN… - JOURNAL OF …, 2010 - ntur.lib.ntu.edu.tw
BACKGROUND & AIMS: Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was
recently approved for the treatment of advanced hepatocellular carcinoma (HCC) …

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.

CH Hsu, YC Shen, ZZ Lin, PJ Chen, YY Shao… - Journal of …, 2010 - europepmc.org
Methods Patients with histologically-or cytologically-proven HCC and Child-Pugh class A
liver function were treated with sorafenib (400mg twice daily) and tegafur/uracil (125 mg/m …

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

CH Hsu, YC Shen, ZZ Lin, PJ Chen… - Journal of …, 2010 - journal-of-hepatology.eu
Background & Aims Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was
recently approved for the treatment of advanced hepatocellular carcinoma (HCC) …

[引用][C] Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

CH HSU, YC SHEN, ZZ LIN, PJ CHEN… - Journal of …, 2010 - pascal-francis.inist.fr
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced
hepatocellular carcinoma CNRS Inist Pascal-Francis CNRS Pascal and Francis …

[引用][C] Phase II study of combining sorafenbi with metronomic tegafur/uracil for advanced hepatocelular carcinoma

HSU CH - J Hepatol., 2010 - cir.nii.ac.jp
Phase II study of combining sorafenbi with metronomic tegafur/uracil for advanced
hepatocelular carcinoma | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

[引用][C] Phase II study of combining sorafenib with metronomic tegafur

CH HSU, YC SHEN, ZZ LIN, PJ CHEN, YY SHAO… - Journal of …, 2010 - Elsevier